Gsk Dividends - GSK

Best deals to access real time data!
Silver Monthly Subscription for only ~~£17.37~~
Level 2 Basic Monthly Subscription for only ~~£62.08~~
UK/US Silver Monthly Subscription for only £30.59
VAT not included

Stock Name	Stock Symbol	Market	Stock Type
Gsk Plc	GSK	London	Ordinary Share

	Price Change	Price Change %	Stock Price	Last Trade
	-27.40	-1.53%	1,765.60	16:35:00

Open Price	Low Price	High Price	Close Price	Previous Close
1,767.80	1,749.60	1,777.40	1,765.60	1,793.00

more quote information »

Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Gsk GSK Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
27/04/2022	1	GBX	14	31/12/2021	31/12/2022	19/05/2022	20/05/2022	01/07/2022	0
09/02/2022	Final	GBX	23	31/12/2020	31/12/2021	24/02/2022	25/02/2022	07/04/2022	80
27/10/2021	1	GBX	19	31/12/2020	31/12/2021	18/11/2021	19/11/2021	13/01/2022	0
28/07/2021	1	GBX	19	31/12/2020	31/12/2021	19/08/2021	20/08/2021	07/10/2021	0
28/04/2021	1	GBX	19	31/12/2020	31/12/2021	20/05/2021	21/05/2021	08/07/2021	0
03/02/2021	Final	GBX	23	31/12/2019	31/12/2020	18/02/2021	19/02/2021	08/04/2021	80
28/10/2020	1	GBX	19	31/12/2019	31/12/2020	12/11/2020	13/11/2020	14/01/2021	0
29/07/2020	1	GBX	19	31/12/2019	31/12/2020	13/08/2020	14/08/2020	08/10/2020	0
29/04/2020	1	GBX	19	31/12/2019	31/12/2020	14/05/2020	15/05/2020	09/07/2020	0
05/02/2020	Final	GBX	23	31/12/2018	31/12/2019	20/02/2020	21/02/2020	09/04/2020	80
30/10/2019	1	GBX	19	31/12/2018	31/12/2019	14/11/2019	15/11/2019	09/01/2020	0
24/07/2019	1	GBX	19	31/12/2018	31/12/2019	08/08/2019	09/08/2019	10/10/2019	0
01/05/2019	1	GBX	19	31/12/2018	31/12/2019	16/05/2019	17/05/2019	11/07/2019	0
06/02/2019	Final	GBX	23	31/12/2017	31/12/2018	21/02/2019	22/02/2019	11/04/2019	80
31/10/2018	1	GBX	19	31/12/2017	31/12/2018	15/11/2018	16/11/2018	10/01/2019	0
25/07/2018	1	GBX	19	31/12/2017	31/12/2018	09/08/2018	10/08/2018	11/10/2018	0
25/04/2018	1	GBX	19	31/12/2017	31/12/2018	10/05/2018	11/05/2018	12/07/2018	0
07/02/2018	Final	GBX	23	31/12/2016	31/12/2017	22/02/2018	23/02/2018	12/04/2018	80
25/10/2017	1	GBX	19	31/12/2016	31/12/2017	09/11/2017	10/11/2017	11/01/2018	0
26/07/2017	1	GBX	19	31/12/2016	31/12/2017	10/08/2017	11/08/2017	12/10/2017	0
26/04/2017	1	GBX	19	31/12/2016	31/12/2017	11/05/2017	12/05/2017	13/07/2017	0
08/02/2017	Final	GBX	23	31/12/2015	31/12/2016	23/02/2017	24/02/2017	13/04/2017	80
26/10/2016	1	GBX	19	31/12/2015	31/12/2016	03/11/2016	04/11/2016	12/01/2017	0
27/07/2016	1	GBX	19	31/12/2015	31/12/2016	11/08/2016	12/08/2016	13/10/2016	0
27/04/2016	1	GBX	19	31/12/2015	31/12/2016	12/05/2016	13/05/2016	14/07/2016	0
03/02/2016	Special	GBX	20	31/12/2014	31/12/2015	18/02/2016	19/02/2016	14/04/2016	0
03/02/2016	Final	GBX	23	31/12/2014	31/12/2015	18/02/2016	19/02/2016	14/04/2016	100
19/10/2015	1	GBX	19	31/12/2014	31/12/2015	12/11/2015	13/11/2015	14/01/2016	0
29/07/2015	1	GBX	19	31/12/2014	31/12/2015	13/08/2015	14/08/2015	01/10/2015	0
06/05/2015	1	GBX	19	31/12/2014	31/12/2015	14/05/2015	15/05/2015	09/07/2015	0
04/02/2015	Final	GBX	23	31/12/2013	31/12/2014	19/02/2015	20/02/2015	09/04/2015	80
22/10/2014	1	GBX	19	31/12/2013	31/12/2014	06/11/2014	07/11/2014	08/01/2015	0
24/07/2014	1	GBX	19	31/12/2013	31/12/2014	06/08/2014	08/08/2014	02/10/2014	0
30/04/2014	1	GBX	19	31/12/2013	31/12/2014	14/05/2014	16/05/2014	10/07/2014	0
05/02/2014	Final	GBX	23	31/12/2012	31/12/2013	19/02/2014	21/02/2014	10/04/2014	78
23/10/2013	1	GBX	19	31/12/2012	31/12/2013	13/11/2013	15/11/2013	09/01/2014	0
24/07/2013	1	GBX	18	31/12/2012	31/12/2013	07/08/2013	09/08/2013	03/10/2013	0
24/04/2013	1	GBX	18	31/12/2012	31/12/2013	08/05/2013	10/05/2013	11/07/2013	0
06/02/2013	Final	GBX	22	31/12/2011	31/12/2012	20/02/2013	22/02/2013	11/04/2013	74
31/10/2012	1	GBX	18	31/12/2011	31/12/2012	14/11/2012	16/11/2012	03/01/2013	0
25/07/2012	1	GBX	17	31/12/2011	31/12/2012	08/08/2012	10/08/2012	04/10/2012	0
25/04/2012	1	GBX	17	31/12/2011	31/12/2012	09/05/2012	11/05/2012	05/07/2012	0
07/02/2012	Special	GBX	5	31/12/2010	31/12/2011	15/02/2012	17/02/2012	12/04/2012	0
07/02/2012	Final	GBX	21	31/12/2010	31/12/2011	15/02/2012	17/02/2012	12/04/2012	75
26/10/2011	Interim	GBX	17	31/12/2010	31/12/2011	02/11/2011	04/11/2011	05/01/2012	0
26/07/2011	Interim	GBX	16	31/12/2010	31/12/2011	03/08/2011	05/08/2011	06/10/2011	0
27/04/2011	Interim	GBX	16	31/12/2010	31/12/2011	04/05/2011	06/05/2011	07/07/2011	0
03/02/2011	Final	GBX	19	31/12/2009	31/12/2010	09/02/2011	11/02/2011	07/04/2011	65
21/10/2010	Interim	GBX	16	31/12/2009	31/12/2010	27/10/2010	29/10/2010	06/01/2011	0
21/07/2010	Interim	GBX	15	31/12/2009	31/12/2010	28/07/2010	30/07/2010	07/10/2010	0
28/04/2010	Interim	GBX	15	31/12/2009	31/12/2010	05/05/2010	07/05/2010	08/07/2010	0
04/02/2010	Final	GBX	18	31/12/2008	31/12/2009	10/02/2010	12/02/2010	08/04/2010	61
29/10/2009	1	GBX	15	31/12/2008	31/12/2009	04/11/2009	06/09/2009	07/01/2010	0
30/07/2009	1	GBX	14	31/12/2008	31/12/2009	31/07/2009	31/07/2009	08/10/2009	28
22/04/2009	1	GBX	14	31/12/2008	31/12/2009	29/04/2009	01/05/2009	09/07/2009	0
05/02/2009	Final	GBX	17	31/12/2007	31/12/2008	11/02/2009	13/02/2009	09/04/2009	57
22/10/2008	1	GBX	14	31/12/2007	31/12/2008	29/10/2008	31/10/2008	09/01/2008	0
07/02/2008	Final	GBX	13	31/12/2006	31/12/2007	13/02/2008	15/02/2008	10/04/2008	53
25/07/2007	1	GBX	12	31/12/2006	31/12/2007	01/08/2007	03/08/2007	11/10/2007	0
24/04/2007	1	GBX	12	31/12/2006	31/12/2007	02/05/2007	04/05/2007	12/07/2007	0
08/02/2007	Final	GBX	0	31/12/2005	31/12/2006	01/01/1970	01/01/1970	01/01/1970	48
08/02/2007	1	GBX	14	31/12/2005	31/12/2006	14/02/2006	16/02/2006	12/04/2007	0
26/10/2006	1	GBX	12	31/12/2005	31/12/2006	01/11/2006	03/11/2006	04/01/2007	0
26/07/2006	1	GBX	11	31/12/2005	31/12/2006	02/08/2006	04/08/2006	05/10/2006	0
27/04/2006	1	GBX	11	31/12/2005	31/12/2006	10/05/2006	12/05/2006	06/07/2006	0
08/02/2006	Final	GBX	14	31/12/2004	31/12/2005	15/02/2006	17/02/2006	06/04/2006	44
27/10/2005	1	GBX	10	31/12/2004	31/12/2005	02/11/2005	04/11/2005	05/01/2006	0
29/07/2005	1	GBX	10	31/12/2004	31/12/2005	03/08/2005	05/08/2005	06/10/2005	0
28/04/2005	1	GBX	10	31/12/2004	31/12/2005	11/05/2005	13/05/2005	07/07/2005	0
10/02/2005	Final	GBX	12	31/12/2003	31/12/2004	16/02/2005	18/02/2005	07/04/2005	42
28/10/2004	1	GBX	10	31/12/2003	31/12/2004	03/11/2004	05/11/2004	06/01/2005	0
27/07/2004	1	GBX	10	31/12/2003	31/12/2004	12/05/2004	14/05/2004	01/07/2004	0
27/07/2004	1	GBX	10	31/12/2003	31/12/2004	04/08/2004	06/08/2004	30/09/2004	0
12/02/2004	Final	GBX	14	31/12/2002	31/12/2003	18/02/2004	20/02/2004	15/04/2004	41
11/02/2004	1	GBX	9	31/12/2002	31/12/2003	29/10/2003	31/10/2003	06/01/2004	0
23/07/2003	1	GBX	9	31/12/2002	31/12/2003	30/07/2003	01/08/2003	02/10/2003	0
30/04/2003	1	GBX	9	31/12/2002	31/12/2003	07/05/2003	09/05/2003	03/07/2003	0
12/02/2003	Final	GBX	13	31/12/2001	31/12/2002	19/02/2003	21/02/2003	17/04/2003	40
23/10/2002	1	GBX	9	30/03/2002	30/09/2002	30/10/2002	01/11/2002	03/01/2003	0
24/07/2002	1	GBX	9	30/12/2001	30/06/2002	31/07/2002	02/08/2002	03/10/2002	0
25/04/2002	1	GBX	9	01/10/2001	31/03/2002	01/05/2002	03/05/2002	04/07/2002	0
14/02/2002	Final	GBX	12	31/12/2000	31/12/2001	20/02/2002	22/02/2002	18/04/2002	39
23/10/2001	1	GBX	9	30/09/2000	30/09/2001	31/10/2001	02/11/2001	03/01/2002	0
24/07/2001	1	GBX	9	30/06/2000	30/06/2001	01/08/2001	03/08/2001	04/10/2001	0
24/04/2001	1	GBX	9	31/03/2000	31/03/2001	02/05/2001	04/05/2001	05/07/2001	0
13/12/2000	Final	GBX	23	31/12/1999	31/12/2000	18/12/2000	22/12/2000	17/04/2001	38
27/07/2000	Interim	GBX	15	30/12/1999	30/06/2000	07/08/2000	11/08/2000	16/10/2000	0
16/02/2000	Final	GBX	22	31/12/1998	31/12/1999	28/02/2000	03/03/2000	25/05/2000	37
29/07/1999	Interim	GBX	15	30/12/1998	30/06/1999	09/08/1999	13/08/1999	01/10/1999	0
18/02/1999	Final	GBX	21	31/12/1997	31/12/1998	01/03/1999	05/03/1999	20/05/1999	36

Top Dividend Posts

Date	Subject
28/6/2022 12:02	mj19: What the brokers say Barclays Capital has trawled through 400-odd-page prospectus and distilled its findings into a far less chunky 23-page overview. Two things struck us from the note. The first, was the indicative valuation range, which, based on a price-to-earnings calculation used to assess companies in the consumer staples sector, comes up well short of the £50bn tentatively tabled by Unilever. Barclays reckons Haleon shares, once listed on July 18, could be worth anywhere from 249p to 416p, which adds up to an equity valuation of £23bn-£38bn. This is based on valuations ‘multiplesR17; ranging from 15 to 25 times earnings. The second interesting ‘takeaway̵7; from the note was the bank’s interaction with key shareholders on the issue organic sales growth – a major driver of the company’s valuation. In the note, Barclays said there was “a degree of scepticism” among investors as to whether Haleon could actually hit the 4%-7% top-line target it has set itself. Indeed, it went on to say there was “significant pushback on our 4.7% medium-term growth forecast”. Jefferies, the American bank that has a stellar reputation in the healthcare sector, has assessed the demerger from GSK’s investment perspective. It believes that by spinning out Haleon, whose stock trade is painkillers such as Advil, the UK pharma group has divested itself of a headache (its words not mine). It has based its ‘buy’ recommendation and £21 a share price target on GSK’s own medium-term growth forecasts – an average 6% increase in sales and 12%-14% compound annual growth in per share earnings. “New GSK is underappreciated, as the number-two growth profile in EU large-caps,” Jefferies said in its note. “We accept New GSK pipeline remains a work-in-progress, but catalysts are starting to emerge, and the vaccines franchise just keeps getting better.” One thing to ponder Those who hold GSK currently as income play (it yields 4.7% or thereabouts currently) will see a cut in the combined GSK/Haleon pay-out post-demerger. It is estimated that GSK will distribute around 44p a share in Haleon 11p, giving a 3.2% yield. Read Full Thread Follow Reply
27/6/2022 06:27	garycook: From the GSK Circular to Shareholders Following Separation, the price of a GSK Share is expected to fall to reflect the demerger of the Haleon Business from the GSK Group. However, Shareholders will have received one Haleon Share for each GSK Share held at the Shareholder Record Time and their retained GSK Shares and their new Haleon Shares will together represent the GSK Shares held by them pre-Separation. The actual aggregate value of those GSK Shares and Haleon Shares will be dependent on their respective market prices post-Separation. In light of this expected fall in the price of a GSK Share, it is proposed that GSK will consolidate its existing share capital to reduce the number of GSK Shares in issue. The intention of the GSK Share Consolidation is to: • reduce the number of GSK Shares which will increase the price of a GSK Share so that there will be general comparability between GSK’s share price before and after the Separation (subject to any interim market movements). This should enable the GSK Group’s earnings per share and share price to be more readily compared to previous financial periods; and • preserve (as far as reasonably possible) the value of options and awards granted under the GSK Executive Schemes and GSK UK Sharesave, thereby avoiding the need for any specific adjustments to the numbers and/or exercise price of options and awards under those schemes Read Full Thread Follow Reply
27/6/2022 05:51	garycook: What will happen to GSK shares when the company splits? Glaxo aims to complete the demerger and listing of its consumer healthcare business, Haleon, by July 18th. Investors will receive one share in Haleon for every existing Glaxo share they own, leaving the pharmaceutical company's investors owning 54.5% of the new business.With the current GSK share price at 1756.20p.Then whatever the Haleon share price is given.This will be deducted from the GSK share price ! eg If you own 1,000 GSK,you will receive 1,000 Haleon.Jonjoneil you are wrong Post 29896.But whatever the share price s of GSK,and Haleon are on July 18 should total around the GSK share price of July 15.eg July 18 around GSK £10,and Haleon 750p ish.Jonjoneil.How do you calculate a GSK share price of £19 ? Read Full Thread Follow Reply
26/6/2022 14:56	zho: >>Looking like maybe around £10 for New GSK>> I don't get that. Glaxo are consolidating GSK shares for reasons of "consistency" - so that the share price after the split looks pretty much as it did before the split. Or at least, that's how I understand this paragraph: "Following completion of the Demerger and listing of Haleon, GSK intends to carry out the GSK Share Consolidation. This is intended to provide consistency in the GSK share price pre- and post-separation (subject to interim market movements), in order to enable comparability between the Company's earnings per share and share price with previous periods." Read Full Thread Follow Reply
26/6/2022 07:28	grupo guitarlumber: Drugs giant GSK says encouraging results from trial of its hepatitis B treatment raises hopes for millions suffering from chronic infection By Neil Craven, Financial Mail on Sunday Published: 21:50 BST, 25 June 2022 \| Updated: 23:17 BST, 25 June 2022 Drugs giant GSK said encouraging results from a trial of its hepatitis B treatment have raised hopes for millions suffering from chronic infection. It estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful. Boost: GSK estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful Boost: GSK estimated its treatment bepirovirsen could generate peak annual sales of more than £2billion ($2.5billion) if later stage trials are successful The development follows positive news earlier this month from a phase three trial in older adults for its RSV vaccine for respiratory disease. Shareholders including activist Elliott view the RSV vaccine, for which GSK will seek approval by the end of the year, as vital for the company's success and are likely to be cheered by the encouraging data on bepirovirsen. How to choose the best (and cheapest) stocks and shares Isa and the right DIY investing platform There are already effective vaccines for hepatitis B. But nearly 300 million people suffer long-lasting complications when the body is unable to fend off the virus. Around 900,000 patients die each year from chronic hepatitis B and, even when treated, it can progress to complications including cirrhosis and liver cancer. The pharmaceutical company said initial results from a mid-stage study raised hopes for what it called a 'functional cure'. Chris Corsico, a senior vice president at the company, said yesterday the treatment has the potential to be 'transformative.' GSK, whose chief executive Dame Emma Walmsley has been under attack by Elliott and other shareholders, is poised to spin off its Sensodyne toothpaste and Advil painkillers consumer healthcare business, Haleon, next month. Read Full Thread Follow Reply
20/6/2022 16:32	jonjoneil: The value of GSK shares will be reduced after Haleon is taken out. I think consolidation is the process of reducing the number of GSK shares to bring the value of each new share to approximate the price immediately before the split. So you will have less GSK plus Haleon (to equal the value of your pre-split holding). So, in theory, if you sold your Haleon shares immediately after issue, and brought new GSK with the proceeds you would end up with the same number of GSK shares that you had pre-split I'm prepared to be corrected. Read Full Thread Follow Reply
18/6/2022 21:47	sajad37: 13:00 What investors need to know as GSK and Pfizer spin off Haleon Some analysts see the valuation well short of the £50bn tabled by Unilever, while others reckon GSK will have divested itself of a major "headache" GSK PLC - Sensodyne is one of Haleon's big brands When Haleon PLC is spun off from GSK PLC (LSE:GSK, NYSE:GSK) next month it is expected to be the biggest stock market listing of the past decade. The indicative valuation is £42bn, which begs the question why did the UK drugs giant and its partner Pfizer turn down a £50bn offer from Unilever? This, we’ll never ascertain. The deal affects thousands of private investors, many former GSK employees. So, here’s what you need to know. Timetable July 6 – Approval for the demerger to be given by shareholders. A formality, the event is convenient for international investors as it is being staged at a hotel within the Terminal 5 complex at Heathrow. July 15 – The first part of the separation process begins. This is being done via what’s called a scrip dividend, which means each GSK investor as of the close on the 14th gets shares in the consumer business. GSK will trade on July 15 without the entitlement to shares in Haleon. Its stock is also being consolidated, which means there will be fewer shares in issue. This is to ensure the impact on the share price of the Haleon demerger is mitigated. July 18 – Haleon shares begin trading in London. July 22 – Haleon’s stock will be listed in the US. July 27 – GSK’s second quarter results. This will be the first glimpse of how the slimmed down GSK is performing. November 10 (or sometime around then) - Pfizer’s ‘lock-up’; ends. So, this is a biggie. Normally, significant shareholders such as Pfizer would be asked not to sell equity for at least six months to allow normal trading patterns to be established post-demerger. In some instances, that lock-up period has been known to extend to 18 months or two years. Pfizer, which will own 32% of Haleon, will be released of that obligation in around four months. While the American drug giant has said it will beat an orderly retreat, the market will view the Pfizer stake as a stock overhang situation. This description imagines the shares are a rock and rubble overhang on a cliff wall that has the potential to dislodge then hit and hurt the climbers below. The stock overhang can hit and hurt the share price. From November 10 on (and probably well before), Haleon stock will be under pressure anticipating Pfizer’s exit. What the brokers say Barclays Capital has trawled through 400-odd-page prospectus and distilled its findings into a far less chunky 23-page overview. Two things struck us from the note. The first, was the indicative valuation range, which, based on a price-to-earnings calculation used to assess companies in the consumer staples sector, comes up well short of the £50bn tentatively tabled by Unilever. Barclays reckons Haleon shares, once listed on July 18, could be worth anywhere from 249p to 416p, which adds up to an equity valuation of £23bn-£38bn. This is based on valuations ‘multiplesR17; ranging from 15 to 25 times earnings. The second interesting ‘takeaway̵7; from the note was the bank’s interaction with key shareholders on the issue organic sales growth – a major driver of the company’s valuation. In the note, Barclays said there was “a degree of scepticism” among investors as to whether Haleon could actually hit the 4%-7% top-line target it has set itself. Indeed, it went on to say there was “significant pushback on our 4.7% medium-term growth forecast”. Jefferies, the American bank that has a stellar reputation in the healthcare sector, has assessed the demerger from GSK’s investment perspective. It believes that by spinning out Haleon, whose stock trade is painkillers such as Advil, the UK pharma group has divested itself of a headache (its words not mine). It has based its ‘buy’ recommendation and £21 a share price target on GSK’s own medium-term growth forecasts – an average 6% increase in sales and 12%-14% compound annual growth in per share earnings. “New GSK is underappreciated, as the number-two growth profile in EU large-caps,” Jefferies said in its note. “We accept New GSK pipeline remains a work-in-progress, but catalysts are starting to emerge, and the vaccines franchise just keeps getting better.” One thing to ponder Those who hold GSK currently as income play (it yields 4.7% or thereabouts currently) will see a cut in the combined GSK/Haleon pay-out post-demerger. It is estimated that GSK will distribute around 44p a share in Haleon 11p. Read Full Thread Follow Reply
10/6/2022 15:14	tradermichael: A brand that brings science and tech to life Today, GSK is a different company from the GlaxoSmithKline that launched in 2000, and the global context around it has shifted radically. Following the proposed demerger of its consumer healthcare business, GSK will focus purely on biopharma, with a new purpose to unite science, technology and talent to get ahead of disease together. To signal the biggest corporate change at GSK for 20 years, we helped redesign GSK’s brand, to bring to life its purpose, strategy, voice and culture. These updates reflect a GSK focused on driving innovation in the field of biopharma, with new ambitions for patients, shareholders and GSK people. A dynamic, flexible and future-ready system GSK's updated brand identity reflects its new purpose: to unite science, technology and talent to get ahead of disease together. Inspired by the striking imagery found in biosciences, the identity features numerous curved forms that evoke the highly adaptable nature of the human immune system. Housed in a redesigned shape, the ‘signal’, the dynamic new GSK logo always points the way ahead. And the identity system flexes, adapts and moves to engage audiences across the many digital, social and physical environments that brands must embrace to thrive in modern times. A brand identity to get ahead of disease together The new branding showcases the amazing diversity of GSK’s people and partners. It represents talent from across its influential worldwide network, including tens of thousands of GSK people, suppliers and innovative partners. In close collaboration with the team at GSK, we developed a branding system that would work for everyone at GSK. The new branding launched in June 2022, and is being rolled out across the business in the coming months. When a logo requires such an explanation, it does not stand alone and is not self-evident! Read Full Thread Follow Reply
01/6/2022 11:12	the grumpy old men: TOP NEWS: GSK files plan for consumer arm demerger with UK regulator Wed, 1st Jun 2022 09:05 Alliance News (Alliance News) - GSK PLC on Wednesday said it has submitted to the UK Financial Conduct Authority its plan for the demerger of its consumer healthcare arm and its listing in London and New York as Haleon. The separation will take the form of a demerger of at least 80% of GSK's current 68% share of the consumer business to GSK shareholders. The remaining 32% of Consumer Healthcare currently is held by US peer Pfizer Inc. Haleon will be listed as ordinary shares in London and as American depositary shares on the New York Stock Exchange. Haleon will provide consumer healthcare products in five categories: Oral Health, Pain Relief, VMS, Respiratory Health, Digestive Health and Other. Oral Health will be its largest component, having contributed 29% of revenue in 2021. GSK will be a pure biopharmaceutical firm, focused on vaccines and specialty medicines. On Tuesday, GSK said it has agreed to pay USD2.1 billion upfront, with potentially a further USD1.2 billion coming, to acquire Boston, Massachusetts-based Affinivax. Affinivax is a clinical-stage biopharmaceutical company focused on developing a novel class of pneumococcal vaccines. GSK on Wednesday said it will carry out a share consolidation following the demerger in order to keep its share price and earnings per share comparable to earlier periods. The company called a general meeting for July 6 at the to approve the plan. The meeting will be held at the Sofitel London Heathrow, Terminal 5 hotel. "The proposed demerger is the most significant corporate change for GSK in the last 20 years, creating two new leading companies, each with clear targets for growth and the ability to positively impact the health and lives of billions of people," GSK said. GSK shares were up 0.2% at 1,736.20 pence early Wednesday in London. By Tom Waite; thomaslwaite@alliancenews.com Read Full Thread Follow Reply
26/4/2022 11:53	tradermichael: Last February, the company said sales in 2022, after the consumer unit spin-off, were expected to grow 5% to 7% and adjusted operating profit was forecast to rise 12% to 14%. Wednesday's results should give: 1. An indicator of how close to these projected (good) figures the company is performing 2. Fuller detail on the 'split'. 3. Further infromation on future dividends:GSK expects to declare a 27p per share dividend payable by the current group for the first half of 2022. This comprises 22 pence per share for new GSK and 5 pence per share representing Consumer Healthcare during the first half whilst part of the group. For the second half of 2022, new GSK continues to expect to declare a 22p per share dividend. As previously communicated, new GSK would expect to declare a dividend of 45 pence per share for 2023. Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

GSK

Gsk

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20220630 22:07:58